L. Stojanovski

发表

Automated design of ligands to polypharmacological profiles

Maria F. Sassano, G. R. Bickerton, Jérémy Besnard, 2012, Nature.

A novel multiple-stage antimalarial agent that inhibits protein synthesis

David W. Gray, E. Winzeler, S. Meister, 2015, Nature.

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani

L. Stojanovski, K. Read, I. Gilbert, 2018, ACS infectious diseases.

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

Michael D. Urbaniak, David W. Gray, G. Drewes, 2018, Nature.

The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1

L. Stojanovski, K. Read, F. Khanim, 2018, Chembiochem : a European journal of chemical biology.

Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs

Robert H Bates, L. Stojanovski, K. Read, 2022, Nature Communications.

PDK1 regulates VDJ recombination, cell-cycle exit and survival during B-cell development

Frederick R. C. Simeons, L. Stojanovski, J. Arthur, 2013, The EMBO journal.

PDK 1 regulates VDJ recombination , cell-cycle exit and survival during B-cell development

Frederick R. C. Simeons, L. Stojanovski, J. Arthur, 2013 .

Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease.

Ana Rodriguez, L. Stojanovski, K. Read, 2020, Journal of medicinal chemistry.

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2020, Journal of medicinal chemistry.

University of Dundee Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2020 .

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma

A. Hill, Frederick R. C. Simeons, L. Stojanovski, 2017 .

Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.

Peter G. Dodd, Frederick R. C. Simeons, L. Stojanovski, 2022, European journal of medicinal chemistry.

University of Dundee Chemical Validation of Methionyl tRNA Synthetase ( MetRS ) as a Druggable Target in Leishmania donovani

Frederick R. C. Simeons, L. Stojanovski, K. Read, 2017 .

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Juan A. Bueren-Calabuig, Andrei V. Pisliakov, David W. Gray, 2019, Proceedings of the National Academy of Sciences.

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

David W. Gray, E. Winzeler, S. Meister, 2016, Journal of medicinal chemistry.

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

E. Winzeler, S. Meister, S. Norval, 2016, Journal of medicinal chemistry.

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2016, eLife.

The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2012, Science Translational Medicine.

Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal Trypanosomiasis

Frederick R. C. Simeons, L. Stojanovski, K. Read, 2022, Journal of medicinal chemistry.

Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2015, Journal of medicinal chemistry.

The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2013, Antimicrobial Agents and Chemotherapy.

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis

Irene Hallyburton, Alan H. Fairlamb, L. Stojanovski, 2010, Biochemical pharmacology.

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Peter G. Dodd, Frederick R. C. Simeons, L. Stojanovski, 2021, Journal of medicinal chemistry.

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Juan A. Bueren-Calabuig, David W. Gray, Frederick R. C. Simeons, 2019, Proceedings of the National Academy of Sciences.

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

David W. Gray, A. Hill, G. Drewes, 2018, Journal of medicinal chemistry.

N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness

Ian H. Gilbert, Chidochangu P. Mpamhanga, Michael Hodgkinson, 2010, Nature.

Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library

David W. Gray, S. Norval, L. Stojanovski, 2015, ChemMedChem.

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

A. Hill, Frederick R. C. Simeons, L. Stojanovski, 2017, Journal of medicinal chemistry.

Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth

A. Korkegian, L. Stojanovski, K. Read, 2021, ACS omega.

Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma bruceiN-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis

Stuart P. McElroy, S. Norval, Frederick R. C. Simeons, 2014, Journal of medicinal chemistry.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Thomas R. Ioerger, Travis Hartman, Tom L. Blundell, 2017, ACS infectious diseases.

A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2018, Journal of medicinal chemistry.

Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode

Stuart P. McElroy, S. Norval, L. Stojanovski, 2015, ChemMedChem.

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani

Ian H Gilbert, Manu De Rycker, Sujatha Manthri, 2017, ACS infectious diseases.

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

Michael D. Urbaniak, G. Drewes, Markus Boesche, 2018, Nature.

Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors

Stuart P. McElroy, S. Norval, L. Stojanovski, 2017, Journal of medicinal chemistry.

Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors

Ian H. Gilbert, Irene Hallyburton, Alan H. Fairlamb, 2011, Journal of medicinal chemistry.

Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

Robert H Bates, L. Stojanovski, K. Read, 2021, Journal of medicinal chemistry.

Lead optimization of a pyrazole sulfonamide series of trypanosoma brucei N myristoyltransferase inhibitors

Stuart P. McElroy, S. Norval, Frederick R. C. Simeons, 2014 .

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

E. Winzeler, S. Meister, J. Rayner, 2016, Nature.

Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.

Peter G. Dodd, Frederick R. C. Simeons, L. Stojanovski, 2023, Journal of medicinal chemistry.

Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static–Cidal Screening of Analogues

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2023, Journal of Medicinal Chemistry.

Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

Michael D. Urbaniak, David W. Gray, G. Drewes, 2023, Nature.

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00203h

S. Norval, Frederick R. C. Simeons, L. Stojanovski, 2020, RSC medicinal chemistry.

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

Michael D. Urbaniak, David W. Gray, G. Drewes, 2018, Nature.